Skip to main content

Advertisement

Figure 2 | Journal of Hematology & Oncology

Figure 2

From: Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

Figure 2

Efficacy results at 24 weeks. (A) Percentage change from baseline in spleen volume for individual patients at week 24. (B) Median percentage change from baseline in spleen length over time. (C) Percentage change from baseline in TSS in individual patients at week 24. (D) Median percentage change in TSS over time. Median dose is shown for patients with available dosing information. TDD, total daily dose; TSS, Total Symptom Score.

Back to article page